MX344586B - Peptidos tomm34 y vacunas que los incluyen. - Google Patents

Peptidos tomm34 y vacunas que los incluyen.

Info

Publication number
MX344586B
MX344586B MX2013006014A MX2013006014A MX344586B MX 344586 B MX344586 B MX 344586B MX 2013006014 A MX2013006014 A MX 2013006014A MX 2013006014 A MX2013006014 A MX 2013006014A MX 344586 B MX344586 B MX 344586B
Authority
MX
Mexico
Prior art keywords
peptides
same
vaccines including
present
tomm34
Prior art date
Application number
MX2013006014A
Other languages
English (en)
Other versions
MX2013006014A (es
Inventor
Nakamura Yusuke
Tsunoda Takuya
Yoshimura Sachiko
Watanabe Tomohisa
Osawa Ryuji
Nakayama Gaku
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2013006014A publication Critical patent/MX2013006014A/es
Publication of MX344586B publication Critical patent/MX344586B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)

Abstract

La presente invención se refiere a péptidos aislados o fragmentos derivados de SEQ ID NO: 42, que enlazan a un antígeno HLA e inducen linfocitos T citotóxicos (CTL). Los péptidos pueden incluir una de las secuencias de aminoácidos anteriormente mencionadas con la sustitución, eliminación, inserción, o adición de uno, dos, o varias secuencias de aminoácido. La presente invención también proporciona composiciones farmacéuticas y métodos para tratar el cáncer que incluyen tales péptidos. Los péptidos de esta invención pueden usarse para tratar cáncer.
MX2013006014A 2010-12-02 2011-11-25 Peptidos tomm34 y vacunas que los incluyen. MX344586B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41918110P 2010-12-02 2010-12-02
PCT/JP2011/006551 WO2012073459A1 (en) 2010-12-02 2011-11-25 Tomm34 peptides and vaccines including the same

Publications (2)

Publication Number Publication Date
MX2013006014A MX2013006014A (es) 2013-07-29
MX344586B true MX344586B (es) 2016-12-20

Family

ID=46171433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006014A MX344586B (es) 2010-12-02 2011-11-25 Peptidos tomm34 y vacunas que los incluyen.

Country Status (22)

Country Link
US (3) US9125849B2 (es)
EP (1) EP2646546B1 (es)
JP (2) JP6064186B2 (es)
KR (1) KR102004900B1 (es)
CN (2) CN105111281A (es)
AR (1) AR084095A1 (es)
AU (1) AU2011336019B2 (es)
BR (1) BR112013013158B1 (es)
CA (1) CA2819463C (es)
CO (1) CO6862100A2 (es)
DK (1) DK2646546T3 (es)
EA (1) EA028216B1 (es)
ES (1) ES2677118T3 (es)
IL (1) IL226068B (es)
MX (1) MX344586B (es)
MY (1) MY166516A (es)
NZ (1) NZ611361A (es)
SG (2) SG190407A1 (es)
TW (1) TWI618541B (es)
UA (1) UA110119C2 (es)
WO (1) WO2012073459A1 (es)
ZA (1) ZA201303886B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107881158B (zh) * 2012-09-11 2021-11-16 肿瘤疗法科学股份有限公司 Ube2t肽及包含它们的疫苗
JP2015228191A (ja) * 2014-06-03 2015-12-17 カシオ計算機株式会社 コンテンツ出力システム、コンテンツ出力方法、コンテンツ出力プログラム、および通信端末
WO2017150084A1 (ja) * 2016-02-29 2017-09-08 京セラドキュメントソリューションズ株式会社 電子機器およびマーカー処理方法
CA3047492C (en) 2017-01-25 2024-01-02 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
CA2047191A1 (en) 1989-02-17 1990-08-18 Hendrik M. Geysen Method for the use and synthesis of peptides
CA2158655A1 (en) * 1993-03-19 1994-09-29 Max L. Birnstiel Process for preparing cancer vaccines
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU2926601A (en) 2000-01-03 2001-07-16 Argonex Pharmaceuticals, Inc. C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
EP2275544A3 (en) * 2002-06-06 2011-03-30 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
EP2270042B1 (en) 2002-09-12 2015-01-14 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
AU2004203749A1 (en) 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
PL1620456T3 (pl) * 2003-04-18 2014-06-30 Ose Pharma Int Sa Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje
AU2006273192B2 (en) * 2005-07-27 2011-09-01 Oncotherapy Science, Inc. Colon cancer related gene TOM34
EP1760089B1 (en) * 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
TWI610939B (zh) * 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
KR101744514B1 (ko) * 2009-03-18 2017-06-08 온코세라피 사이언스 가부시키가이샤 Ｎｅｉｌ3 펩티드 및 이를 포함하는 백신

Also Published As

Publication number Publication date
TWI618541B (zh) 2018-03-21
SG190407A1 (en) 2013-06-28
MX2013006014A (es) 2013-07-29
EP2646546A4 (en) 2015-12-23
CN105111281A (zh) 2015-12-02
KR102004900B1 (ko) 2019-07-29
EA028216B1 (ru) 2017-10-31
CN103339253B (zh) 2015-09-09
EP2646546B1 (en) 2018-05-16
AR084095A1 (es) 2013-04-17
EA201390811A1 (ru) 2013-12-30
MY166516A (en) 2018-07-05
US9585948B2 (en) 2017-03-07
CA2819463C (en) 2018-10-23
US20170198010A1 (en) 2017-07-13
CN103339253A (zh) 2013-10-02
WO2012073459A1 (en) 2012-06-07
AU2011336019B2 (en) 2016-07-07
IL226068A0 (en) 2013-06-27
KR20130121910A (ko) 2013-11-06
JP6064186B2 (ja) 2017-01-25
SG10201509823WA (en) 2015-12-30
JP2016222676A (ja) 2016-12-28
CA2819463A1 (en) 2012-06-07
AU2011336019A1 (en) 2013-07-04
EP2646546A1 (en) 2013-10-09
JP2014506114A (ja) 2014-03-13
US9125849B2 (en) 2015-09-08
BR112013013158B1 (pt) 2020-04-28
TW201225973A (en) 2012-07-01
IL226068B (en) 2019-01-31
UA110119C2 (xx) 2015-11-25
US20150374810A1 (en) 2015-12-31
ZA201303886B (en) 2014-03-26
CO6862100A2 (es) 2014-02-10
BR112013013158A2 (pt) 2017-08-01
NZ611361A (en) 2014-10-31
ES2677118T3 (es) 2018-07-30
US20140023671A1 (en) 2014-01-23
DK2646546T3 (en) 2018-08-06

Similar Documents

Publication Publication Date Title
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.
GB201019331D0 (en) Methods for the diagnosis and treatment of cancer based on AVL9
EP2528937A4 (en) MODIFIED MELK PEPTIDES AND ASSOCIATED VACCINES
MX2009007261A (es) Vacuna de peptido foxp3.
MX2013014489A (es) Peptidos sema5b y vacunas que incluyen los mismos.
MY166516A (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EP2513136A4 (en) PEPTIDES TMEM22 AND VACCINES COMPRISING THEM
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
MX342000B (es) Peptidos ect2 y vacunas que los incluyen.
EP2370454A4 (en) PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM

Legal Events

Date Code Title Description
FG Grant or registration